-
-
-
[1] Sender R, Fuchs S, Milo R.Are We Really Vastly Outnumbered?Revisiting the Ratio of Bacterial to Host Cells in Humans[J].Cell, 2016, 164(3):337-340.
[2] Org E, Parks BW, Joo JW, et al.Genetic and environmental control of host-gut microbiota interactions[J].Genome Res, 2015, 25(10):1558-1569.
[3] Muegge BD, Kuczynski J, Knights D, et al.Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans[J].Science, 2011, 332(6032):970-974.
[4] Thaiss CA, Zmora N, Levy M, et al.The microbiome and innate immunity[J].Nature, 2016, 535(7610):65-74.
[5] Zoetendal EG, Raes J, van den Bogert B, et al.The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates[J].Isme J, 2012, 6(7):1415-1426.
[6] Bonnet M, Buc E, Sauvanet P, et al.Colonization of the human gut by E.coli and colorectal cancer risk[J].Clin Cancer Res, 2014, 20(4):859-867.
[7] Roerecke M, Rehm J.Alcohol use disorders and mortality:a systematic review and meta-analysis[J].Addiction, 2013, 108(9):1562-1578.
[8] Pande C, Kumar A, Sarin S K.Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease[J].Aliment Pharmacol Ther, 2009, 29(12):1273-1281.
[9] Starkel P, Schnabl B.Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease[J].Semin Liver Dis, 2016, 36(4):331-339.
[10] Kirpich I A, Solovieva NV, Leikhter SN, et al.Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury:a pilot study[J].Alcohol, 2008, 42(8):675-682.
[11] Mutlu EA, Gillevet PM, Rangwala H, et al.Colonic microbiome is altered in alcoholism[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302(9):G966-G978.
[12] Leclercq S, Matamoros S, Cani PD, et al.Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity[J].Proc Natl Acad Sci USA, 2014, 111(42):E4485-E4493.
[13] Wang L, Fouts DE, Starkel P, et al.Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation[J].Cell Host Microbe, 2016, 19(2):227-239.
[14] Lunia M K, Sharma B C, Sharma P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:a randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12(6):1003-1008.
[15] Nobili V, Bedogni G, Alisi A, et al.A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease[J].Arch Dis Child, 2009, 94(10):801-805.
[16] El K A, Armougom F, Gordon JI, et al.The abundance and variety of carbohydrate-active enzymes in the human gut microbiota[J].Nat Rev Microbiol, 2013, 11(7):497-504.
[17] Zhu L, Baker SS, Gill C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH) patients:a connection between endogenous alcohol and NASH[J].Hepatology, 2013, 57(2):601-609.
[18] Wong VW, Tse CH, Lam TT, et al.Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis——a longitudinal study[J].PLoS One, 2013, 8(4):e62885.
[19] Malaguarnera M, Vacante M, Antic T, et al.Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J].Dig Dis Sci, 2012, 57(2):545-553.
[20] Daubioul CA, Horsmans Y, Lambert P, et al.Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis:results of a pilot study[J].Eur J Clin Nutr, 2005, 59(5):723-726.
[21] Malaguarnera M, Vacante M, Antic T, et al.Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J].Dig Dis Sci, 2012, 57(2):545-553.
[22] Eaton JE, Talwalkar JA, Lazaridis KN, et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management[J].Gastroenterology, 2013, 145(3):521-536.
[23] Torres J, Bao X, Goel A, et al.The features of mucosa-associated microbiota in primary sclerosing cholangitis[J].Aliment Pharmacol Ther, 2016, 43(7):790-801.
[24] Iwasawa K, Suda W, Tsunoda T, et al.Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis[J].Gut, 2017, 66(7):1344-1346.
[25] Sabino J, Vieira-Silva S, Machiels K, et al.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J].Gut, 2016, 65(10):1681-1689.
[26] Farkkila M, Karvonen AL, Nurmi H, et al.Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis:a randomized placebo-controlled trial[J].Hepatology, 2004, 40(6):1379-1386.
[27] Tabibian JH, Weeding E, Jorgensen RA, et al.Randomised clinical trial:vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study[J].Aliment Pharmacol Ther, 2013, 37(6):604-612.
[28] Chen Y, Yang F, Lu H, et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology, 2011, 54(2):562-572.
[29] Bajaj JS, Heuman DM, Hylemon PB, et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol, 2014, 60(5):940-947.
[30] Qin N, Yang F, Li A, et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature, 2014, 513(7516):59-64.
[31] Gluud LL, Vilstrup H, Morgan MY.Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J].Cochrane Database Syst Rev, 2016, 6(5):CD003044.
[32] Bajaj JS, Heuman DM, Hylemon PB, et al.Randomised clinical trial:Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J].Aliment Pharmacol Ther, 2014, 39(10):1113-1125.
[33] Kaji K, Takaya H, Saikawa S, et al.Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity[J].World J Gastroenterol, 2017, 23(47):8355-8366.
-
计量
- 文章访问数: 185
- PDF下载数: 249
- 施引文献: 0
下载: